FDA Approves Talazoparib for BRCA-Mutated, HER2-Negative Breast Cancer

October 16, 2018 – The FDA has approved talazoparib for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer, according to Pfizer, the manufacturer of the PARP inhibitor. In addition, the FDA approved the BRACAnalysis CDx test, developed by Myriad Genetic Laboratories, Inc., to identify patients with breast cancer with deleterious or suspected deleterious germline BRCA-mutated … (leggi tutto)